display
Mainz (dpa) - The Mainz corona vaccine manufacturer Biontech achieved a quarterly profit of 1.1 billion euros in the first quarter of this year.
Compared to the fourth quarter of 2020 (366.9 million), this means a tripling of net profit, according to the company on Monday.
In the first quarter of 2020, Biontech had to accept a net loss of 53 million euros - the main reason for this was high research and development costs.
The biotechnology company's sales rose even faster.
Sales in the first three months reached an estimated 2.05 billion euros.
That was more than 70 times as much as in the corresponding period in 2020 (27.7 million).
The increase was mainly due to the rapid increase in the global supply of the corona vaccine, the company said.
By May 6, more than 450 million vaccine doses had been delivered to 91 countries or regions worldwide.
To this end, Biontech has teamed up with the US pharmaceutical giant Pfizer.
© dpa-infocom, dpa: 210510-99-541367 / 2
display
Biontech